Scientists are finding ways to hack the genetic code.
|
Amicus Therapeutics takes an unusual approach to genetic disease.
|
Biotech firm GlycoFi shows that yeast can improve drug function by helping control the drug’s molecular structure.
|
The CEO of Sirna Therapeutics discusses the first human trials of a drug candidate based on breakthrough RNAi technology.
|
Cardinal Health backs out of secondary market; a survey suggests consumers are skeptical of new drug safety; health minister shirks anti-AIDS targets.
|
Big pharma needs help slouching toward functional genomics.
|
A biotech upstart stays under wraps, working to reinvent drug discovery.
|
Dealflow: ICO-Teledesic triumphs with $1 billion; Goodhome grabs $30 million; Broadband-bundler Ceon bags $29 million.
|
Proteomics will be bigger than genomics. And Illumina could be one of its most promising practitioners.
|